|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
638,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$60,375,372 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
57 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lewis Alan |
Director |
|
2012-11-07 |
4 |
S |
$46.80 |
$702,000 |
D/D |
(15,000) |
15,900 |
|
- |
|
Lewis Alan |
Director |
|
2012-11-07 |
4 |
OE |
$17.33 |
$259,950 |
D/D |
15,000 |
30,900 |
|
- |
|
Heron Elaine J |
Director |
|
2012-11-07 |
4 |
S |
$46.44 |
$4,876,116 |
D/D |
(105,000) |
45,900 |
|
- |
|
Heron Elaine J |
Director |
|
2012-11-07 |
4 |
OE |
$7.46 |
$1,726,350 |
D/D |
105,000 |
150,900 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-11-05 |
4 |
AS |
$46.00 |
$2,840,000 |
D/D |
(60,000) |
100,413 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-11-05 |
4 |
OE |
$17.33 |
$1,045,212 |
D/D |
60,000 |
126,183 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-11-05 |
4 |
AS |
$46.00 |
$460,000 |
D/D |
(10,000) |
52,277 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-11-05 |
4 |
OE |
$11.05 |
$110,500 |
D/D |
10,000 |
62,277 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2012-11-05 |
4 |
AS |
$46.00 |
$376,250 |
D/D |
(8,000) |
15,340 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2012-11-05 |
4 |
OE |
$14.39 |
$115,120 |
D/D |
8,000 |
23,340 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-11-02 |
4 |
GA |
$0.00 |
$0 |
I/I |
161 |
5,563 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-11-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
161 |
55,025 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-11-01 |
4 |
AS |
$37.08 |
$185,384 |
D/D |
(5,000) |
52,277 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2012-11-01 |
4 |
OE |
$11.05 |
$55,250 |
D/D |
5,000 |
57,277 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2012-10-31 |
5 |
B |
$21.76 |
$3,503 |
D/D |
161 |
100,574 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2012-10-31 |
5 |
B |
$21.76 |
$11,924 |
D/D |
548 |
15,294 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2012-10-31 |
5 |
B |
$27.91 |
$16,408 |
D/D |
588 |
23,245 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2012-10-31 |
4 |
A |
$21.76 |
$5,766 |
D/D |
265 |
10,835 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2012-10-31 |
4 |
A |
$21.76 |
$2,372 |
D/D |
109 |
52,760 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-10-31 |
4 |
AS |
$37.68 |
$151,856 |
D/D |
(4,000) |
174,691 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-10-31 |
4 |
OE |
$9.86 |
$29,580 |
D/D |
3,000 |
178,691 |
|
- |
|
Bienaime Jean Jacques |
Chief Business Officer |
|
2012-10-23 |
5 |
GA |
$0.00 |
$0 |
I/I |
13,545 |
13,545 |
|
- |
|
Bienaime Jean Jacques |
Chief Business Officer |
|
2012-10-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
13,545 |
135,901 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-10-22 |
4 |
AS |
$41.86 |
$125,578 |
D/D |
(3,000) |
175,691 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2012-10-22 |
4 |
OE |
$9.86 |
$29,580 |
D/D |
3,000 |
178,691 |
|
- |
|
1303 Records found
|
|
Page 17 of 53 |
|
|